Delivery Order SPE2DB24D1201-SPE2DB25FJDUJ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) injectable medication in 3 ml vials, with a contract ceiling value of $2,418.83. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded without set-aside...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. This competitively awarded, firm fixed-price delivery order has a ceiling value of $9,330.09 with an ultimate completion date of August 6, 2025. The pharmaceutical product will be delivered to the company's distribution facility in Conshohocken, Pennsylvania, serving federal defense and military healthcare...
- The Defense Logistics Agency awarded a $5,168.91 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) in 3 ml vials. This is a firm fixed price, non-set-aside contract with a place of performance in Conshohocken, Pennsylvania, and an ultimate completion date of August 5, 2025. The delivery order represents a small-value pharmaceutical procurement executed through a competitive contracting process. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $42,011.63. This firm fixed-price delivery order, which is set to be completed by August 5, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement within the Defense Logistics Agency's medical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials, valued at $31,332.93. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle running through December 2026. The performance...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials, with a ceiling value of $3,494.97. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a delivery order issued under a larger federal contract vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) in 3 ml vials, with a contract ceiling value of $5,243.63. This firm fixed-price delivery order, which has an ultimate completion date of July 25, 2025, will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The award utilized no set-aside designation and was competitively awarded through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) prefilled syringes with a ceiling value of $7,519.92. This is a firm fixed price delivery order with an ultimate completion date of July 30, 2025, and performance will be executed from the vendor's location in Conshohocken, Pennsylvania. The contract represents a non-competitive set-aside award, indicating that AmerisourceBergen was selected...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with a ceiling value of $10,491.72. This competitively awarded, non-set-aside contract is structured as a firm fixed price delivery order and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with a ceiling value of $18,294.14. This competitively awarded, firm fixed-price delivery order is set to be completed by July 31, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJDUJDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) injectable medication in 3 mL vials, with a contract ceiling value of $11,564.20. This non-set-aside, competitively awarded delivery order reflects firm fixed pricing and is scheduled for completion by August 6, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, a major pharmaceutical distributor and healthcare solutions provider, leverages this comprehensive global pharmaceutical support vehicle to supply a broad range of medications and medical commodities to support military healthcare programs and federal medical procurement needs. The company's contract portfolio demonstrates consistent capability in fulfilling federal medical supply requirements across multiple therapeutic domains, including endocrinology treatments like Ozempic for diabetes management.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.6k | 8/5/25 |